Literature DB >> 19422301

Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.

Sheng Pan1, Lihua Cheng, James T White, Wei Lu, Angelita G Utleg, Xiaowei Yan, Nicole D Urban, Charles W Drescher, Leroy Hood, Biaoyang Lin.   

Abstract

Chemotherapy with carboplatin and paclitaxel is the standard treatment for ovarian cancer patients. Although most patients initially respond to this treatment, few are cured. Resistance to chemotherapy is the major cause of treatment failure. We applied a quantitative proteomic approach based on ICAT/MS/MS technology to analyze tissues harvested at primary debulking surgery before the initiation of combination chemotherapy in order to identify potential naive or intrinsic chemotherapy response proteins in ovarian cancers. We identified 44 proteins that are overexpressed, and 34 proteins that are underexpressed in the chemosensitive tissue compared to the chemoresistant tissue. The overexpressed proteins identified in the chemoresistant tissue include 10 proteins (25.6%) belonging to the extracellular matrix (ECM), including decorin, versican, basigin (CD147), fibulin-1, extracellular matrix protein 1, biglycan, fibronectin 1, dermatopontin, alpha-cardiac actin (smooth muscle actin), and an EGF-containing fibulin-like extracellular matrix protein 1. Interesting proteins identified as overexpressed in the chemosensitive tissue include gamma-catenin (junction plakoglobin) and delta-catenin, tumor suppressor p53-binding protein 1 (53BP1), insulin-like growth factor-binding protein 2 (IGFBP2), proliferating cell nuclear antigen (PCNA), annexin A11, and 53 kDa selenium binding protein 1. Integrative analysis with expression profiling data of eight chemoresistant tissues and 13 chemosensitive tissues revealed that 16 proteins showed consistent changes at both the protein and the RNA levels. These include P53 binding protein 1, catenin delta 1 and plakoglobin, EGF-containing fibulin-like extracellular matrix protein 1 and voltage-dependent anion-selective channel protein 1. Our results suggest that chemotherapy response may be determined by multiple and complex system properties involving extracellular-matrix, cell adhesion and junction proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422301      PMCID: PMC6469530          DOI: 10.1089/omi.2009.0008

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  37 in total

1.  Interconnected contribution of tissue morphogenesis and the nuclear protein NuMA to the DNA damage response.

Authors:  Pierre-Alexandre Vidi; Gurushankar Chandramouly; Matthew Gray; Lei Wang; Er Liu; Joseph J Kim; Vassilis Roukos; Mina J Bissell; Prabhas V Moghe; Sophie A Lelièvre
Journal:  J Cell Sci       Date:  2012-02-13       Impact factor: 5.285

Review 2.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

3.  Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance.

Authors:  Jian Gao; Zhenhua Hu; Juanjuan Liu; Dawo Liu; Yanyan Wang; Mingbo Cai; Danye Zhang; Mingzi Tan; Bei Lin
Journal:  Med Oncol       Date:  2014-04-02       Impact factor: 3.064

Review 4.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

5.  53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.

Authors:  Shuhui Hong; Xiaoyan Li; Ying Zhao; Qifeng Yang; Beihua Kong
Journal:  Oncol Lett       Date:  2018-04-27       Impact factor: 2.967

6.  Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.

Authors:  Yiqing Qu; Yie Yang; Baoyi Liu; Wei Xiao
Journal:  Med Oncol       Date:  2009-12-10       Impact factor: 3.064

7.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

8.  Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum.

Authors:  Kristin Lm Boylan; John D Andersen; Lorraine B Anderson; LeeAnn Higgins; Amy Pn Skubitz
Journal:  Proteome Sci       Date:  2010-06-14       Impact factor: 2.480

9.  Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

Authors:  John D Andersen; Kristin Lm Boylan; Ronald Jemmerson; Melissa A Geller; Benjamin Misemer; Katherine M Harrington; Starchild Weivoda; Bruce A Witthuhn; Peter Argenta; Rachel Isaksson Vogel; Amy Pn Skubitz
Journal:  J Ovarian Res       Date:  2010-09-10       Impact factor: 4.234

10.  Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction.

Authors:  Bin Liu; Tonghong Xu; Xinning Xu; Yuzhu Cui; Xiaojing Xing
Journal:  Mol Cell Biochem       Date:  2018-05-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.